<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109485</url>
  </required_header>
  <id_info>
    <org_study_id>JPN-P-2010-1</org_study_id>
    <nct_id>NCT01109485</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to further evaluate the safety of Olopatadine Ophthalmic
      Solution 0.1% in Japanese children with allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire about compliance with dosing instructions</measure>
    <time_frame>4 weeks</time_frame>
    <description>(1;always &gt;90% 2;often 75-90% 3;sometimes 50-75% 4;seldom &lt;50%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in score of subjective symptoms and objective findings</measure>
    <time_frame>4 weeks</time_frame>
    <description>(0;none 1;mild 2;moderate 3;severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire about stinging after instillation</measure>
    <time_frame>4 weeks</time_frame>
    <description>(1;none 2;mild 3;moderate 4;severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Olopatadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olopatadine hydrochloride ophthalmic solution 0.1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride ophthalmic solution 0.1%</intervention_name>
    <description>1-2 drops 4 times per day</description>
    <arm_group_label>Olopatadine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose parents or guardians can issue informed consent

          -  Patients aged over 7 and less than 16 at the baseline

          -  Patients confirmed to show type I allergy

          -  Patients with allergic conjunctivitis

          -  Patients having subjective symptoms at the baseline (itching sensation, foreign body
             sensation, eye pain, etc.)

        Exclusion Criteria:

          -  Patients having ocular itching sensation and injection caused by disease other than
             allergic conjunctivitis

          -  Patients having retinal detachment, diabetic retinopathy or progressive retinal
             disease

          -  Patients with a history of ocular infection, corneal herpes or relapsing corneal
             erosion of sudden onset or secondary to corneal injury

          -  Patients having received continuous treatment with corticosteroid within 3 months

          -  Patients having received immunotherapy

          -  Patients requiring continuous treatment of corticosteroid, immunosuppressors,
             non-steroidal anti-inflammatory agents, vasoconstrictors, anti-histamines,
             anti-allergy agents, herbal preparations indicated for &quot;conjunctivitis&quot; or any
             ophthalmic solution other than the test product

          -  Patients having undergone ocular laser therapy within 3 months

          -  Unilaterally blind patients (best corrected visual acuity: below 0.01)

          -  Patients with a history of allergy or hypersensitivity to olopatadine hydrochloride

          -  Patients necessitating the use of contact lens during the study period

          -  Other patients judged by the attending physician as inappropriate for study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eriko Chono</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center For Trial Locations</name>
      <address>
        <city>Tokyo</city>
        <zip>1F</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

